Lung cancer has traditionally been classified by histology. However, a greater
understanding of disease biology and the identification of oncogenic driver alterations has …

Lung cancer is the leading cause of cancer-related deaths in North America and other
developed countries. One of the reasons lung cancer is at the top of the list is that it is often …

Background Targeted inhibition of the PD-L1–PD-1 pathway might be further amplified
through combination of PD-1 or PD-L1 inhibitors with novel anti-TIGIT inhibitory immune …

Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a
strong evidence base for use in patients with cancer. The European Society for Medical …

Background Human epidermal growth factor receptor 2 (HER2)–targeted therapies have not
been approved for patients with non–small-cell lung cancer (NSCLC). The efficacy and …

Oncogenic RET fusions occur in diverse cancers. Pralsetinib is a potent, selective inhibitor of
RET receptor tyrosine kinase. ARROW (NCT03037385, ongoing) was designed to evaluate …

PURPOSE We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus
ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …

Abstract Introduction In CheckMate 227, nivolumab plus ipilimumab prolonged overall
survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD …

PURPOSE Resistance to immune checkpoint inhibition (ICI) in advanced non–small-cell
lung cancer (NSCLC) represents a major unmet need. Combining ICI with vascular …